Physician profile
Ali Khalil
NPI 1417186578
$701.62
in general payments reported to CMS, 2019-2025
14 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.58 · 2020: $24.30 · 2021: $108 · 2022: $75.86 · 2023: $108 · 2024: $23.61 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.57 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $203.69 | 2023-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals Lp | $131.71 | 2019-2023 | Lokelma |
| Takeda Pharmaceuticals U.S.A., INC. | $62.06 | 2022-2024 | Livtencity |
| Novo Nordisk INC | $53.50 | 2022-2025 | Ozempic |
| One Lambda, INC. | $48.63 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.09 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $29.69 | 2025 | Tarpeyo |
| Veloxis Pharmaceuticals, INC. | $28.59 | 2025 | Envarsus |
| Invivyd INC | $26.97 | 2025 | Pemgarda |
| Lundbeck LLC | $18.69 | 2022 | |
| Vifor Pharma, INC. | $18.54 | 2019 | |
| Amgen INC. | $17.68 | 2025 | Tavneos |
| Horizon Therapeutics Plc | $15.84 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.